EN | UA
EN | UA

Help Support

Back

How ideal the biosimilar CT-P10 is for rheumatoid arthritis treatment?

How ideal the biosimilar CT-P10 is for rheumatoid arthritis treatment? How ideal the biosimilar CT-P10 is for rheumatoid arthritis treatment?
How ideal the biosimilar CT-P10 is for rheumatoid arthritis treatment? How ideal the biosimilar CT-P10 is for rheumatoid arthritis treatment?

What's new?

Evidence supports the approval of biosimilar CT-P10 in terms of efficacy and safety for long term use in the treatment of patients with rheumatoid arthritis. 

The biosimilar CT-P10 presents similar pharmacodynamics, immunogenicity, pharmacokinetics, long-term efficacy and safety as of US-RTX and EU-RTX (Rituximab) and can be used for rheumatoid arthritis and other CD20+ B-cell-related diseases, apparent from the finding of a recently done 48-week multinational, randomized, double-blind trial.

Three hundred seventy-two participants with active RA were selected and categorized into two groups . The groups were administered either with two intravenous infusions of CT-P10 or 1000 mg US-RTX, or EU-RTX two weeks apart. Afterwards, patients went through a second course regardless of the clinical response. American College of Rheumatology (ACR) response rates and Disease Activity Score 28-joint count (DAS28) were estimated as the efficacy endpoints. Patients were also evaluated for safety, immunogenicity, pharmacodynamics, and pharmacokinetics.

A total of 330 participants out of 372 went for the second treatment course. CT-P10 group showed similar improvements in DAS28-C-reactive protein, Health Assessment Questionnaire Disability Index, Short Form 36-Item Health Survey at week 48 as of US-RTX, and EU-RTX groups. The pharmacokinetic, pharmacodynamic and safety profiles were also similar between the groups. In the case of immunogenicity, 9.4%, 8.6%, and 4.9% of patients from US-RTX, EU-RTX, and CT-P10 groups were found to have anti-drug antibodies at week 48. The findings of all the groups were similar which exhibits CT-P10 as a potential treatment. 

Source:

BioDrugs

Article:

Long-Term Efficacy and Safety of Biosimilar CT-P10 Versus Innovator Rituximab in Rheumatoid Arthritis: 48-Week Results from a Randomized Phase III Trial.

Authors:

Chang-Hee Suh et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: